Associations - RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)

RAF1 amplification	Melanoma	RAF1 amplification	Melanoma	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B
5-genomic mutation signature	Non Small Cell Lung Cancer	5-genomic mutation signature	Non Small Cell Lung Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
FGFR1 amplification + RAF1 ampliﬁcation + CDK6 ampliﬁcation	Small Cell Lung Cancer	FGFR1 amplification + RAF1 ampliﬁcation + CDK6 ampliﬁcation	Small Cell Lung Cancer	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4
FGFR1 amplification + RAF1 ampliﬁcation + CDK6 ampliﬁcation	Small Cell Lung Cancer	FGFR1 amplification + RAF1 ampliﬁcation + CDK6 ampliﬁcation	Small Cell Lung Cancer	ponatinib Resistant: C4 – Case Studies ponatinib Resistant : C4	ponatinib Resistant: C4 – Case Studies ponatinib Resistant : C4
FGFR1 amplification + RAF1 ampliﬁcation + MYC ampliﬁcation	Small Cell Lung Cancer	FGFR1 amplification + RAF1 ampliﬁcation + MYC ampliﬁcation	Small Cell Lung Cancer	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4
RAF1 R256S	Colon Cancer	RAF1 R256S	Colon Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
GOLGA4-RAF1 fusion	Cutaneous Melanoma	GOLGA4-RAF1 fusion	Cutaneous Melanoma	MEK inhibitor Sensitive: C4 – Case Studies MEK inhibitor Sensitive : C4	MEK inhibitor Sensitive: C4 – Case Studies MEK inhibitor Sensitive : C4
QKI-RAF1 fusion	Spindle Cell Sarcoma	QKI-RAF1 fusion	Spindle Cell Sarcoma	trametinib Sensitive: C4 – Case Studies trametinib Sensitive : C4	trametinib Sensitive: C4 – Case Studies trametinib Sensitive : C4
QKI-RAF1 fusion	Spindle Cell Sarcoma	QKI-RAF1 fusion	Spindle Cell Sarcoma	temozolomide + irinotecan Resistant: C4 – Case Studies temozolomide + irinotecan Resistant : C4	temozolomide + irinotecan Resistant: C4 – Case Studies temozolomide + irinotecan Resistant : C4
KANK4-RAF1 fusion	Pancreatic Cancer	KANK4-RAF1 fusion	Pancreatic Cancer	sorafenib Sensitive: C4 – Case Studies sorafenib Sensitive : C4	sorafenib Sensitive: C4 – Case Studies sorafenib Sensitive : C4
ESRP1-RAF1 fusion	Prostate Cancer	ESRP1-RAF1 fusion	Prostate Cancer	sorafenib Sensitive: D – Preclinical sorafenib Sensitive : D	sorafenib Sensitive: D – Preclinical sorafenib Sensitive : D
ESRP1-RAF1 fusion	Prostate Cancer	ESRP1-RAF1 fusion	Prostate Cancer	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D

RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)

Associations(15)

Associations
(15)